Semler Scientific Competitors

Semler Scientific (OTCMKTS:SMLR) and InMode (NASDAQ:INMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Valuation and Earnings

This table compares Semler Scientific and InMode's revenue, earnings per share and valuation.

InMode has higher revenue and earnings than Semler Scientific. InMode is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Semler Scientific and InMode's net margins, return on equity and return on assets.

Institutional and Insider Ownership

12.1% of Semler Scientific shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 13.6% of Semler Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Semler Scientific has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Semler Scientific and InMode, as provided by MarketBeat.

Semler Scientific currently has a consensus target price of $110.50, indicating a potential upside of 8.33%. InMode has a consensus target price of $71.50, indicating a potential upside of 5.30%. Given Semler Scientific's higher probable upside, analysts plainly believe Semler Scientific is more favorable than InMode.

Summary

Semler Scientific beats InMode on 7 of the 13 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and Semler Scientific (OTCMKTS:SMLR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings for Outset Medical and Semler Scientific, as reported by MarketBeat.com.

Outset Medical currently has a consensus price target of $55.00, indicating a potential upside of 10.86%. Semler Scientific has a consensus price target of $110.50, indicating a potential upside of 8.33%. Given Outset Medical's higher probable upside, research analysts clearly believe Outset Medical is more favorable than Semler Scientific.

Valuation & Earnings

This table compares Outset Medical and Semler Scientific's gross revenue, earnings per share and valuation.

Semler Scientific has higher revenue and earnings than Outset Medical.

Profitability

This table compares Outset Medical and Semler Scientific's net margins, return on equity and return on assets.

Insider and Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 12.1% of Semler Scientific shares are owned by institutional investors. 13.6% of Semler Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Semler Scientific beats Outset Medical on 6 of the 9 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Institutional & Insider Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 12.1% of Semler Scientific shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by company insiders. Comparatively, 13.6% of Semler Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares BioLife Solutions and Semler Scientific's revenue, earnings per share (EPS) and valuation.

Semler Scientific has higher revenue and earnings than BioLife Solutions. Semler Scientific is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioLife Solutions and Semler Scientific, as reported by MarketBeat.com.

BioLife Solutions currently has a consensus target price of $32.4444, suggesting a potential downside of 10.57%. Semler Scientific has a consensus target price of $110.50, suggesting a potential upside of 8.33%. Given Semler Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Semler Scientific is more favorable than BioLife Solutions.

Profitability

This table compares BioLife Solutions and Semler Scientific's net margins, return on equity and return on assets.

Risk & Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Summary

Semler Scientific beats BioLife Solutions on 9 of the 14 factors compared between the two stocks.

Semler Scientific (OTCMKTS:SMLR) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Risk & Volatility

Semler Scientific has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.

Insider & Institutional Ownership

12.1% of Semler Scientific shares are owned by institutional investors. Comparatively, 76.7% of TransMedics Group shares are owned by institutional investors. 13.6% of Semler Scientific shares are owned by company insiders. Comparatively, 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Semler Scientific and TransMedics Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Semler Scientific and TransMedics Group, as reported by MarketBeat.com.

Semler Scientific presently has a consensus price target of $110.50, suggesting a potential upside of 8.33%. TransMedics Group has a consensus price target of $36.60, suggesting a potential upside of 14.30%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Semler Scientific.

Earnings & Valuation

This table compares Semler Scientific and TransMedics Group's revenue, earnings per share (EPS) and valuation.

Semler Scientific has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Semler Scientific beats TransMedics Group on 9 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Risk & Volatility

Natus Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Natus Medical and Semler Scientific, as provided by MarketBeat.

Semler Scientific has a consensus target price of $110.50, indicating a potential upside of 8.33%. Given Semler Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Semler Scientific is more favorable than Natus Medical.

Earnings and Valuation

This table compares Natus Medical and Semler Scientific's gross revenue, earnings per share (EPS) and valuation.

Semler Scientific has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Natus Medical and Semler Scientific's net margins, return on equity and return on assets.

Institutional and Insider Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 12.1% of Semler Scientific shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by insiders. Comparatively, 13.6% of Semler Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Semler Scientific beats Natus Medical on 12 of the 14 factors compared between the two stocks.

Semler Scientific (OTCMKTS:SMLR) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Institutional & Insider Ownership

12.1% of Semler Scientific shares are held by institutional investors. Comparatively, 78.4% of AxoGen shares are held by institutional investors. 13.6% of Semler Scientific shares are held by company insiders. Comparatively, 6.9% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Semler Scientific and AxoGen, as reported by MarketBeat.

Semler Scientific presently has a consensus price target of $110.50, suggesting a potential upside of 8.33%. AxoGen has a consensus price target of $23.75, suggesting a potential upside of 19.17%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than Semler Scientific.

Profitability

This table compares Semler Scientific and AxoGen's net margins, return on equity and return on assets.

Risk and Volatility

Semler Scientific has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares Semler Scientific and AxoGen's top-line revenue, earnings per share and valuation.

Semler Scientific has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Semler Scientific beats AxoGen on 10 of the 14 factors compared between the two stocks.